27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Kite Pharma Inc (NASDAQ: KITE) recently announced that it will be partnering with bluebird bio Inc (NASDAQ: BLUE) to develop second generation T-cell receptor product candidates.
Arie Belldegrun, Kite Pharma CEO, was recently on CNBC to shed some light on T-cell therapy the company is developing and testing currently and the future of immunotherapy.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Clinical Trials Are Ongoing
"About a month ago we have started a multi-centre clinical trial across the United States, where we are delivering for the first time this treatment," Belldegrun began. "It comes out from a central manufacturing place and it's being shipped directly to the hospital and this therapy is now becoming available under the clinical trial to multiple centres around the country."
T-cell Therapy: Next Generation Immunotherapy
Belldegrun was asked if he sees this therapy becoming more mainstream and part of the first regimen that patients take. He replied, "When you start something that has never been done before that the FDA has never seen any application for approval this type of treatments, you want to start with end stage patients that have no other hopes."
"But as with many other drugs, some of which I personally developed we start with the worst type of patients and then you move slowly to the mainstream oncology. But what we need to understand, this is immunotherapy...there are different types of immunotherapy. What we are talking here is a [gene] T-cell therapy."
"It's different than the entire buzz that's happening around what's called checkpoint inhibitors, this is a multi-billion dollar new market of immunotherapy. But as exciting as it is, what we are offering here is the next generation immunotherapy, it's engineering your own T-cell to recognize only cancer cells and sparing healthy cells," Belldegrun said.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.